Q8T Stock Overview
OrbusNeich Medical Group Holdings Limited, an investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
OrbusNeich Medical Group Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.43 |
| 52 Week High | HK$1.59 |
| 52 Week Low | HK$0.33 |
| Beta | 0 |
| 1 Month Change | 25.15% |
| 3 Month Change | -28.07% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| Q8T | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 11.5% | -0.6% | -1.4% |
| 1Y | n/a | -9.6% | 2.2% |
Return vs Industry: Insufficient data to determine how Q8T performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how Q8T performed against the German Market.
Price Volatility
| Q8T volatility | |
|---|---|
| Q8T Average Weekly Movement | 17.7% |
| Medical Equipment Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: Q8T's share price has been volatile over the past 3 months.
Volatility Over Time: Q8T's weekly volatility has increased from 11% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,249 | David Chien | orbusneich.com |
OrbusNeich Medical Group Holdings Limited, an investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, stents for implantation, non-compliant balloons for post-dilatation, and specialty catheters, as well as sirolimus-eluting coronary stents, peripheral self-expandable stents, and paclitaxel-coated PTCA and PTA balloons. Its product portfolio covers various treatment processes in percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures.
OrbusNeich Medical Group Holdings Limited Fundamentals Summary
| Q8T fundamental statistics | |
|---|---|
| Market cap | €371.82m |
| Earnings (TTM) | €42.22m |
| Revenue (TTM) | €144.14m |
8.8x
P/E Ratio2.6x
P/S RatioIs Q8T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| Q8T income statement (TTM) | |
|---|---|
| Revenue | US$153.87m |
| Cost of Revenue | US$47.37m |
| Gross Profit | US$106.50m |
| Other Expenses | US$61.43m |
| Earnings | US$45.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.054 |
| Gross Margin | 69.22% |
| Net Profit Margin | 29.29% |
| Debt/Equity Ratio | 1.1% |
How did Q8T perform over the long term?
See historical performance and comparison